The phosphorylation of the IR/IGF-1R has been noted across breast cancer sub-types, with 48.1% IR/IGF-1R phosphorylation in luminal, 64.3% in HER2-overexpressing, and 41.9% in TNBC cases examined (138). Here, IGF1R is linked to breast carcinoma.